# A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Source: https://onco.cc/trials/nct06907043/  
OnCo record `nct06907043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EIK1004-001 (IMP1707-001) in advanced solid tumours, run by Eikon Therapeutics, now recruiting.

## Summary

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT06907043 by Eikon Therapeutics, with 130 participants planned, started 2025-04-30 and due to reach its primary completion in 2028-12. Interventions recorded: EIK1004-001 (IMP1707-001).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06907043
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors
- Sponsor: Eikon Therapeutics
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06907043: https://clinicaltrials.gov/study/NCT06907043

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06907043.json